FDA Denies Xyvona Name for Sun Pharma's Levorphanol Tartrate, Triggering Nationwide Recall
SUN PHARMACEUTICAL INDUSTRIES INC has initiated a nationwide recall of Xyvona (levorphanol tartrate tablets) due to FDA denial of the proprietary name. This voluntary action, stemming from a labeling issue at Ohm Laboratories Inc. in New Brunswick, NJ, adds to Sun Pharma's extensive regulatory history, signaling persistent compliance challenges for procurement and regulatory teams.
FDA Marketing Denial Triggers Nationwide Recall of Xyvona (Levorphanol Tartrate)
On May 22, 2026, SUN PHARMACEUTICAL INDUSTRIES INC initiated a voluntary, nationwide recall of its product, Xyvona (levorphanol tartrate tablets), 3mg, 100 Tablets. This action, reported to the FDA on June 10, 2026, directly resulted from the FDA's denial of marketing authorization for the proprietary name "Xyvona." For procurement directors and regulatory affairs heads, this signifies a critical regulatory hurdle where a product's market access is halted not due to a quality defect, but a specific labeling and naming issue. The classification of the reason for recall as "Labeling: Not Elsewhere Classified" underscores the nuanced nature of regulatory compliance beyond manufacturing quality. This event impacts the availability of a specific lot, AE11393, with an expiration date of October 2027. Business development executives must recognize that even seemingly minor regulatory discrepancies, such as a proprietary name denial, can lead to significant market disruption and necessitate costly recall procedures, affecting product launch timelines and revenue projections. The recall of a Schedule II controlled substance like levorphanol tartrate further emphasizes the stringent regulatory environment and the high stakes involved in every aspect of drug approval and commercialization within the United States market.
Manufacturing Origin: Ohm Laboratories Inc.'s Role in Sun Pharma's Portfolio
The recalled Xyvona (levorphanol tartrate tablets) product was manufactured by Ohm Laboratories Inc., located in New Brunswick, NJ 08901, a key facility within the SUN PHARMACEUTICAL INDUSTRIES INC network. While distributed by Forte Bio-Pharma, LLC., Las Vegas, NV 89113, the manufacturing site's compliance directly impacts the parent company's market standing. For supply chain VPs, understanding the specific manufacturing origin is crucial for assessing potential vulnerabilities and ensuring robust supplier qualification processes. Levorphanol tartrate is an opioid analgesic, a Schedule II controlled substance, which places additional scrutiny on its manufacturing and distribution. Any disruption, even one related to labeling, can have amplified consequences given the critical nature of such medications. This event highlights that regulatory compliance at the manufacturing facility extends beyond Good Manufacturing Practices (GMP) to encompass all aspects of product presentation and regulatory submission. The ongoing status of this recall means that the affected product remains off the market, necessitating immediate action for any downstream partners or healthcare providers relying on this specific lot for patient care. This underscores the need for continuous monitoring of manufacturing partners, even for issues that may appear peripheral to core production quality.
Supply Chain Disruption for Levorphanol Tartrate Buyers in the United States
The nationwide distribution pattern of the recalled Xyvona (levorphanol tartrate tablets) means that procurement directors across the United States must immediately assess their inventory and sourcing strategies for this critical opioid analgesic. The recall specifically impacts lot number AE11393, which carries an expiration date of October 2027. This targeted recall, while not affecting all batches, still necessitates a comprehensive review of stock and potential supply gaps for healthcare systems and pharmacies. For supply chain VPs, the disruption underscores the importance of real-time inventory tracking and robust recall management protocols to minimize patient impact and financial losses. The denial of a proprietary name, while distinct from manufacturing defects, still results in product removal, creating an immediate need for alternative sourcing. Business development executives should note that such events can erode market confidence and lead to shifts in purchasing patterns, as buyers prioritize suppliers with impeccable regulatory records. The challenge is particularly acute for controlled substances, where alternative sources may be limited and qualification processes lengthy, potentially leading to supply shortages if not proactively managed. This incident serves as a clear signal to diversify supplier bases and maintain contingency plans for essential medicines.
Navigating Alternative Sourcing for Critical APIs Amidst Regulatory Challenges
Given the recall of Xyvona (levorphanol tartrate tablets) and the broader regulatory history of SUN PHARMACEUTICAL INDUSTRIES INC, procurement teams must critically evaluate their sourcing strategies for levorphanol tartrate and other key APIs. While the KNOWLEDGE GRAPH does not specify alternative suppliers for levorphanol tartrate, the absence of readily named alternatives underscores a significant risk. For procurement directors, this means a proactive approach to identifying and qualifying secondary or tertiary sources is paramount, especially for controlled substances where supply chains are often tightly controlled and market entry barriers are high. Qualification timelines for new suppliers can extend from 12 to 24 months, making immediate diversification challenging. Regulatory affairs heads should initiate due diligence on potential new suppliers, focusing on their FDA compliance history, manufacturing capabilities, and regulatory submission track record. The geographic diversity of potential suppliers should also be considered to mitigate risks associated with regional regulatory changes or geopolitical events. This event reinforces the commercial imperative to move beyond single-source reliance, even for niche or specialized products, to safeguard against unforeseen regulatory actions that can abruptly halt supply and impact patient access.
SUN PHARMACEUTICAL INDUSTRIES INC's Pattern of Recurring Regulatory Challenges
This recall of Xyvona (levorphanol tartrate tablets) is not an isolated incident for SUN PHARMACEUTICAL INDUSTRIES INC but rather a continuation of a persistent pattern of regulatory actions by the FDA. The company has faced a significant number of recalls and compliance issues across various products and manufacturing sites since early 2024. For regulatory affairs heads and supply chain VPs, this extensive history signals a systemic risk profile that demands heightened scrutiny. Recent events include a Class II recall of Mesalamine Tablets in January 2024 due to microbial contamination, followed by another Mesalamine Extended-Release Capsules recall in March 2024 for dissolution failure. Febuxostat Tablets faced a microbial contamination recall in March 2024, and Amphotericin B was recalled in May 2024 for assay failure. XELPROS (Latanoprost) saw a recall in May 2024 due to particulate matter, and Nitrofurantoin recalls were terminated in July 2024 amidst recurring dissolution failures. The trend continued into 2025 with Class II recalls for Morphine Sulfate ER Tablets (dissolution failure in March), Gabapentin (cross-contamination in April), Lisdexamfetamine Dimesylate (dissolution failure in July), and Technetium Tc 99m Mertiatide Kits (dissolution failure in September). Even in 2026, prior to the Xyvona recall, Sun Pharma faced a Class III recall for Fluocinolone Acetonide Solution (impurity specifications in January) and a Class II recall for Diclofenac Sodium Gel (viscosity specifications in February), alongside a Fluocinonide recall in April. This consistent stream of issues, ranging from contamination and dissolution failures to impurity and now labeling, indicates fundamental challenges in quality control and regulatory adherence across Sun Pharma's operations. This history should prompt procurement teams to re-evaluate the risk premiums associated with sourcing from this manufacturer and consider the potential for increased FDA oversight or future enforcement actions.
Strategic Imperatives for Risk Mitigation and Supplier Due Diligence
The ongoing recall of Xyvona (levorphanol tartrate tablets) by SUN PHARMACEUTICAL INDUSTRIES INC, coupled with its extensive history of regulatory non-compliance, presents clear strategic imperatives for senior decision-makers. Procurement directors must implement enhanced due diligence protocols for all current and prospective suppliers, particularly those with a documented pattern of FDA actions. This includes not only evaluating manufacturing quality systems but also scrutinizing regulatory submission processes and labeling controls. Supply chain VPs should prioritize supplier diversification to mitigate the impact of single-point failures or regulatory disruptions. Relying heavily on a single manufacturer, especially one with a high frequency of recalls, introduces unacceptable levels of risk for critical drug products. Business development executives need to factor in these regulatory risks when forecasting market entry and product stability, understanding that a supplier's compliance record directly impacts commercial viability and brand reputation. Regulatory affairs heads should proactively engage with suppliers to understand their corrective and preventive action (CAPA) plans for past issues and assess the robustness of their quality management systems. The cumulative effect of these events suggests that the FDA may intensify its scrutiny of Sun Pharma's facilities, potentially leading to more frequent inspections or stricter enforcement. This necessitates a strategic shift towards partners demonstrating consistent, impeccable regulatory compliance to ensure uninterrupted supply and market access for essential chemical and life science products.